Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2014-07

AUTHORS

Christian M. Zechmann, Ali Afshar-Oromieh, Tom Armor, James B. Stubbs, Walter Mier, Boris Hadaschik, John Joyal, Klaus Kopka, Jürgen Debus, John W. Babich, Uwe Haberkorn

ABSTRACT

INTRODUCTION: Since the prostate-specific membrane antigen (PSMA) is frequently over-expressed in prostate cancer (PCa) several PSMA-targeting molecules are under development to detect and treat metastatic castration resistant prostate cancer (mCRPC). We investigated the tissue kinetics of a small molecule inhibitor of PSMA ((S)-2-(3-((S)-1-carboxy-5-(3-(4-[(124)I]iodophenyl)ureido)pentyl)ureido)pentanedioicacid; MIP-1095) using PET/CT to estimate radiation dosimetry for the potential therapeutic use of (131)I-MIP-1095 in men with mCRPC. We also report preliminary safety and efficacy of the first 28 consecutive patients treated under a compassionate-use protocol with a single cycle of (131)I-MIP-1095. METHODS: Sixteen patients with known prostate cancer underwent PET/CT imaging after i.v. administration of (124)I-MIP-1095 (mean activity: 67.4 MBq). Each patient was scanned using PET/CT up to five times at 1, 4, 24, 48 and 72 h post injection. Volumes of interest were defined for tumor lesions and normal organs at each time point followed by dose calculations using the OLINDA/EXM software. Twenty-eight men with mCRPC were treated with a single cycle of (131)I-MIP-1095 (mean activity: 4.8 GBq, range 2 to 7.2 GBq) and followed for safety and efficacy. Baseline and follow up examinations included a complete blood count, liver and kidney function tests, and measurement of serum PSA. RESULTS: I-124-MIP-1095 PET/CT images showed excellent tumor uptake and moderate uptake in liver, proximal intestine and within a few hours post-injection also in the kidneys. High uptake values were observed only in salivary and lacrimal glands. Dosimetry estimates for I-131-MIP-1095 revealed that the highest absorbed doses were delivered to the salivary glands (3.8 mSv/MBq, liver (1.7 mSv/MBq) and kidneys (1.4 mSv/MBq). The absorbed dose calculated for the red marrow was 0.37 mSv/MBq. PSA values decreased by >50 % in 60.7 % of the men treated. Of men with bone pain, 84.6 % showed complete or moderate reduction in pain. Hematological toxicities were mild. Of men treated, 25 % had a transient slight to moderate dry mouth. No adverse effects on renal function were observed. CONCLUSION: Based on the biodistribution and dose calculations of the PSMA-targeted small molecule (124)I-MIP-1095 therapy with the authentic analog (131)I-MIP-1095 enables a targeted tumor therapy with unprecedented doses delivered to the tumor lesions. Involved lymph node and bone metastases were exposed to estimated absorbed doses upwards of 300 Gy. More... »

PAGES

1280-1292

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00259-014-2713-y

DOI

http://dx.doi.org/10.1007/s00259-014-2713-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1031124841

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/24577951


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antigens, Surface", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glutamate Carboxypeptidase II", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glutamates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Iodine Radioisotopes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Molecular Targeted Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Organs at Risk", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Positron-Emission Tomography", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostatic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radiometry", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radiopharmaceuticals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radiotherapy Dosage", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Safety", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tomography, X-Ray Computed", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Urea", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University Hospital Heidelberg", 
          "id": "https://www.grid.ac/institutes/grid.5253.1", 
          "name": [
            "Department of Nuclear Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zechmann", 
        "givenName": "Christian M.", 
        "id": "sg:person.01252656365.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01252656365.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University Hospital Heidelberg", 
          "id": "https://www.grid.ac/institutes/grid.5253.1", 
          "name": [
            "Department of Nuclear Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Afshar-Oromieh", 
        "givenName": "Ali", 
        "id": "sg:person.0601051525.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601051525.56"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Progenics Pharmaceuticals (United States)", 
          "id": "https://www.grid.ac/institutes/grid.280766.d", 
          "name": [
            "Molecular Insight Pharmaceuticals, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Armor", 
        "givenName": "Tom", 
        "id": "sg:person.0711165337.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0711165337.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Radiation Dosimetry Systems RDS, Inc., Apharetta, GA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stubbs", 
        "givenName": "James B.", 
        "id": "sg:person.0716664422.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716664422.63"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University Hospital Heidelberg", 
          "id": "https://www.grid.ac/institutes/grid.5253.1", 
          "name": [
            "Department of Nuclear Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mier", 
        "givenName": "Walter", 
        "id": "sg:person.01216712431.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216712431.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University Hospital Heidelberg", 
          "id": "https://www.grid.ac/institutes/grid.5253.1", 
          "name": [
            "Department of Urology, University Hospital Heidelberg, Heidelberg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hadaschik", 
        "givenName": "Boris", 
        "id": "sg:person.01107613315.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01107613315.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Progenics Pharmaceuticals (United States)", 
          "id": "https://www.grid.ac/institutes/grid.280766.d", 
          "name": [
            "Molecular Insight Pharmaceuticals, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Joyal", 
        "givenName": "John", 
        "id": "sg:person.0634105510.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0634105510.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "German Cancer Research Center", 
          "id": "https://www.grid.ac/institutes/grid.7497.d", 
          "name": [
            "Division Radiopharmaceutical Chemistry, DKFZ, Heidelberg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kopka", 
        "givenName": "Klaus", 
        "id": "sg:person.01370431444.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01370431444.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University Hospital Heidelberg", 
          "id": "https://www.grid.ac/institutes/grid.5253.1", 
          "name": [
            "Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Debus", 
        "givenName": "J\u00fcrgen", 
        "id": "sg:person.013541325272.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013541325272.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cornell University", 
          "id": "https://www.grid.ac/institutes/grid.5386.8", 
          "name": [
            "Molecular Insight Pharmaceuticals, Boston, MA, USA", 
            "Division of Radiopharmacy, Department of Radiology, Cornell University, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Babich", 
        "givenName": "John W.", 
        "id": "sg:person.0702220710.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0702220710.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "German Cancer Research Center", 
          "id": "https://www.grid.ac/institutes/grid.7497.d", 
          "name": [
            "Department of Nuclear Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany", 
            "Clinical Cooperation Unit Nuclear Medicine, DKFZ, Heidelberg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Haberkorn", 
        "givenName": "Uwe", 
        "id": "sg:person.01142772466.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142772466.17"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/bjc.2012.523", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003810699", 
          "https://doi.org/10.1038/bjc.2012.523"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2559.2007.02635.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004893542"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-13-0231", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005760736"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2004.09.154", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008865143"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3322/caac.20107", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009055747"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0360-3016(91)90171-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011986935"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-09-1682", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023217681"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-1004-0023", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027571060"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0022-5347(01)62921-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031823081"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-12-3779", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032142025"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.05.160", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042646898"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2967/jnumed.112.111203", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044994053"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ijc.2910620511", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045484440"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1146/annurev-pharmtox-011112-140341", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046666670"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jcb.10661", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048747192"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/bc200279b", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055154669"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/jm800994j", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055955945"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/jm800994j", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055955945"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074708152", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077048096", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077061647", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083346985", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-07", 
    "datePublishedReg": "2014-07-01", 
    "description": "INTRODUCTION: Since the prostate-specific membrane antigen (PSMA) is frequently over-expressed in prostate cancer (PCa) several PSMA-targeting molecules are under development to detect and treat metastatic castration resistant prostate cancer (mCRPC). We investigated the tissue kinetics of a small molecule inhibitor of PSMA ((S)-2-(3-((S)-1-carboxy-5-(3-(4-[(124)I]iodophenyl)ureido)pentyl)ureido)pentanedioicacid; MIP-1095) using PET/CT to estimate radiation dosimetry for the potential therapeutic use of (131)I-MIP-1095 in men with mCRPC. We also report preliminary safety and efficacy of the first 28 consecutive patients treated under a compassionate-use protocol with a single cycle of (131)I-MIP-1095.\nMETHODS: Sixteen patients with known prostate cancer underwent PET/CT imaging after i.v. administration of (124)I-MIP-1095 (mean activity: 67.4 MBq). Each patient was scanned using PET/CT up to five times at 1, 4, 24, 48 and 72 h post injection. Volumes of interest were defined for tumor lesions and normal organs at each time point followed by dose calculations using the OLINDA/EXM software. Twenty-eight men with mCRPC were treated with a single cycle of (131)I-MIP-1095 (mean activity: 4.8 GBq, range 2 to 7.2 GBq) and followed for safety and efficacy. Baseline and follow up examinations included a complete blood count, liver and kidney function tests, and measurement of serum PSA.\nRESULTS: I-124-MIP-1095 PET/CT images showed excellent tumor uptake and moderate uptake in liver, proximal intestine and within a few hours post-injection also in the kidneys. High uptake values were observed only in salivary and lacrimal glands. Dosimetry estimates for I-131-MIP-1095 revealed that the highest absorbed doses were delivered to the salivary glands (3.8 mSv/MBq, liver (1.7 mSv/MBq) and kidneys (1.4 mSv/MBq). The absorbed dose calculated for the red marrow was 0.37 mSv/MBq. PSA values decreased by >50 % in 60.7 % of the men treated. Of men with bone pain, 84.6 % showed complete or moderate reduction in pain. Hematological toxicities were mild. Of men treated, 25 % had a transient slight to moderate dry mouth. No adverse effects on renal function were observed.\nCONCLUSION: Based on the biodistribution and dose calculations of the PSMA-targeted small molecule (124)I-MIP-1095 therapy with the authentic analog (131)I-MIP-1095 enables a targeted tumor therapy with unprecedented doses delivered to the tumor lesions. Involved lymph node and bone metastases were exposed to estimated absorbed doses upwards of 300 Gy.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00259-014-2713-y", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1297401", 
        "issn": [
          "1619-7070", 
          "1619-7089"
        ], 
        "name": "European Journal of Nuclear Medicine and Molecular Imaging", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "7", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "41"
      }
    ], 
    "name": "Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy", 
    "pagination": "1280-1292", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "94466b2b7e2a789e87aeb7814cbd53b2ba0049e56b84c0a64c553bf8b37b53ea"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "24577951"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101140988"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00259-014-2713-y"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1031124841"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00259-014-2713-y", 
      "https://app.dimensions.ai/details/publication/pub.1031124841"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T10:04", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000347_0000000347/records_89826_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs00259-014-2713-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00259-014-2713-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00259-014-2713-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00259-014-2713-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00259-014-2713-y'


 

This table displays all metadata directly associated to this object as RDF triples.

295 TRIPLES      21 PREDICATES      70 URIs      41 LITERALS      29 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00259-014-2713-y schema:about N0bc540014da94cb992a6a455e667a238
2 N0c51c5f3205248c9a30d4e814ba920bb
3 N0cb7ba2dd6e34b27b0866936357e470e
4 N11c6d91e81a94c99b85041a384b8612c
5 N156d9b5f9dce42bba4c236f5d17aa578
6 N1b395c485fb84364bce2ce976b3e1fda
7 N2409f22cbe8b469a8870bde764cf6c5c
8 N34a1c7334c3c44a995df7d8e90daff5b
9 N46d970bf04ad4b1f9a2fe7fcc5c91851
10 N485414dfba934e019b79091b6708856c
11 N536619ef49664e5fac43fb4a525612c3
12 N797df27ab3c44bf0bc4b5c58114536e8
13 N8ac517f84ef34d47af93e0838be359ca
14 N956ad5cad40b418ab25937587add4119
15 Na705ffc090c946c4a817dd67be479907
16 Nd5172e3f8b1f4df08b59973e3f12e931
17 Ndc5578bff0c14c5db6c6ec18f33f3e18
18 Ne134e1993d4440de87f5eb8bfa41badf
19 Ne408980ac6f74fe985db9cc80f2d38f2
20 Nf9550ff1f6514b5e9d847c201cc38e9a
21 anzsrc-for:11
22 anzsrc-for:1103
23 schema:author N4eca43b275e24988ac68cc3320de32af
24 schema:citation sg:pub.10.1038/bjc.2012.523
25 https://app.dimensions.ai/details/publication/pub.1074708152
26 https://app.dimensions.ai/details/publication/pub.1077048096
27 https://app.dimensions.ai/details/publication/pub.1077061647
28 https://app.dimensions.ai/details/publication/pub.1083346985
29 https://doi.org/10.1002/ijc.2910620511
30 https://doi.org/10.1002/jcb.10661
31 https://doi.org/10.1016/0360-3016(91)90171-y
32 https://doi.org/10.1016/s0022-5347(01)62921-5
33 https://doi.org/10.1021/bc200279b
34 https://doi.org/10.1021/jm800994j
35 https://doi.org/10.1111/j.1365-2559.2007.02635.x
36 https://doi.org/10.1146/annurev-pharmtox-011112-140341
37 https://doi.org/10.1158/0008-5472.can-09-1682
38 https://doi.org/10.1158/1078-0432.ccr-1004-0023
39 https://doi.org/10.1158/1078-0432.ccr-12-3779
40 https://doi.org/10.1158/1078-0432.ccr-13-0231
41 https://doi.org/10.1200/jco.2004.09.154
42 https://doi.org/10.1200/jco.2005.05.160
43 https://doi.org/10.2967/jnumed.112.111203
44 https://doi.org/10.3322/caac.20107
45 schema:datePublished 2014-07
46 schema:datePublishedReg 2014-07-01
47 schema:description INTRODUCTION: Since the prostate-specific membrane antigen (PSMA) is frequently over-expressed in prostate cancer (PCa) several PSMA-targeting molecules are under development to detect and treat metastatic castration resistant prostate cancer (mCRPC). We investigated the tissue kinetics of a small molecule inhibitor of PSMA ((S)-2-(3-((S)-1-carboxy-5-(3-(4-[(124)I]iodophenyl)ureido)pentyl)ureido)pentanedioicacid; MIP-1095) using PET/CT to estimate radiation dosimetry for the potential therapeutic use of (131)I-MIP-1095 in men with mCRPC. We also report preliminary safety and efficacy of the first 28 consecutive patients treated under a compassionate-use protocol with a single cycle of (131)I-MIP-1095. METHODS: Sixteen patients with known prostate cancer underwent PET/CT imaging after i.v. administration of (124)I-MIP-1095 (mean activity: 67.4 MBq). Each patient was scanned using PET/CT up to five times at 1, 4, 24, 48 and 72 h post injection. Volumes of interest were defined for tumor lesions and normal organs at each time point followed by dose calculations using the OLINDA/EXM software. Twenty-eight men with mCRPC were treated with a single cycle of (131)I-MIP-1095 (mean activity: 4.8 GBq, range 2 to 7.2 GBq) and followed for safety and efficacy. Baseline and follow up examinations included a complete blood count, liver and kidney function tests, and measurement of serum PSA. RESULTS: I-124-MIP-1095 PET/CT images showed excellent tumor uptake and moderate uptake in liver, proximal intestine and within a few hours post-injection also in the kidneys. High uptake values were observed only in salivary and lacrimal glands. Dosimetry estimates for I-131-MIP-1095 revealed that the highest absorbed doses were delivered to the salivary glands (3.8 mSv/MBq, liver (1.7 mSv/MBq) and kidneys (1.4 mSv/MBq). The absorbed dose calculated for the red marrow was 0.37 mSv/MBq. PSA values decreased by >50 % in 60.7 % of the men treated. Of men with bone pain, 84.6 % showed complete or moderate reduction in pain. Hematological toxicities were mild. Of men treated, 25 % had a transient slight to moderate dry mouth. No adverse effects on renal function were observed. CONCLUSION: Based on the biodistribution and dose calculations of the PSMA-targeted small molecule (124)I-MIP-1095 therapy with the authentic analog (131)I-MIP-1095 enables a targeted tumor therapy with unprecedented doses delivered to the tumor lesions. Involved lymph node and bone metastases were exposed to estimated absorbed doses upwards of 300 Gy.
48 schema:genre research_article
49 schema:inLanguage en
50 schema:isAccessibleForFree true
51 schema:isPartOf N3514fa5dd2e1480f86820e5abcdd41a5
52 N7820598b41864d44a9d4d150528a8579
53 sg:journal.1297401
54 schema:name Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy
55 schema:pagination 1280-1292
56 schema:productId N67c566b1843f4d5db31beb82d48d57da
57 N72c33d4b2fee44c08ee2f07754de558c
58 Nc7d52f00f24541a4bb14de1dc8c3ac4f
59 Ne353b3b8f7ec483e98b92fdd87579263
60 Ne68d9c6abbc04c4eb93d87e44ad556a5
61 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031124841
62 https://doi.org/10.1007/s00259-014-2713-y
63 schema:sdDatePublished 2019-04-11T10:04
64 schema:sdLicense https://scigraph.springernature.com/explorer/license/
65 schema:sdPublisher N1dc2fb5806724237b527f71d04c6c9a0
66 schema:url http://link.springer.com/10.1007%2Fs00259-014-2713-y
67 sgo:license sg:explorer/license/
68 sgo:sdDataset articles
69 rdf:type schema:ScholarlyArticle
70 N0bc540014da94cb992a6a455e667a238 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name Glutamate Carboxypeptidase II
72 rdf:type schema:DefinedTerm
73 N0c51c5f3205248c9a30d4e814ba920bb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Positron-Emission Tomography
75 rdf:type schema:DefinedTerm
76 N0cb7ba2dd6e34b27b0866936357e470e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Male
78 rdf:type schema:DefinedTerm
79 N11c6d91e81a94c99b85041a384b8612c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Radiometry
81 rdf:type schema:DefinedTerm
82 N156d9b5f9dce42bba4c236f5d17aa578 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Humans
84 rdf:type schema:DefinedTerm
85 N192abaf637fe48b49c80566b293ddba5 rdf:first sg:person.0716664422.63
86 rdf:rest N60ea396ba5414deda228583bc084ef04
87 N1aa660140a3240f4b0b1ec34e7f880c2 rdf:first sg:person.0601051525.56
88 rdf:rest N1b05afa767014bb39f510a31d896b548
89 N1b05afa767014bb39f510a31d896b548 rdf:first sg:person.0711165337.36
90 rdf:rest N192abaf637fe48b49c80566b293ddba5
91 N1b395c485fb84364bce2ce976b3e1fda schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Middle Aged
93 rdf:type schema:DefinedTerm
94 N1dc2fb5806724237b527f71d04c6c9a0 schema:name Springer Nature - SN SciGraph project
95 rdf:type schema:Organization
96 N2409f22cbe8b469a8870bde764cf6c5c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Antigens, Surface
98 rdf:type schema:DefinedTerm
99 N34a1c7334c3c44a995df7d8e90daff5b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Neoplasm Metastasis
101 rdf:type schema:DefinedTerm
102 N3514fa5dd2e1480f86820e5abcdd41a5 schema:volumeNumber 41
103 rdf:type schema:PublicationVolume
104 N46316fc5bcbd461fb2e2d3fd8abc514b rdf:first sg:person.0702220710.66
105 rdf:rest Nd3536140c6dc4ecabc2721152cd6eb10
106 N46d970bf04ad4b1f9a2fe7fcc5c91851 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Tomography, X-Ray Computed
108 rdf:type schema:DefinedTerm
109 N485414dfba934e019b79091b6708856c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Glutamates
111 rdf:type schema:DefinedTerm
112 N4eca43b275e24988ac68cc3320de32af rdf:first sg:person.01252656365.95
113 rdf:rest N1aa660140a3240f4b0b1ec34e7f880c2
114 N536619ef49664e5fac43fb4a525612c3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Iodine Radioisotopes
116 rdf:type schema:DefinedTerm
117 N60ea396ba5414deda228583bc084ef04 rdf:first sg:person.01216712431.54
118 rdf:rest Ne2aa36bebdcf4d7d8e34ce9bc494e802
119 N67c566b1843f4d5db31beb82d48d57da schema:name dimensions_id
120 schema:value pub.1031124841
121 rdf:type schema:PropertyValue
122 N72c33d4b2fee44c08ee2f07754de558c schema:name pubmed_id
123 schema:value 24577951
124 rdf:type schema:PropertyValue
125 N7820598b41864d44a9d4d150528a8579 schema:issueNumber 7
126 rdf:type schema:PublicationIssue
127 N797df27ab3c44bf0bc4b5c58114536e8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Organs at Risk
129 rdf:type schema:DefinedTerm
130 N8ac517f84ef34d47af93e0838be359ca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Radiotherapy Dosage
132 rdf:type schema:DefinedTerm
133 N956ad5cad40b418ab25937587add4119 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Urea
135 rdf:type schema:DefinedTerm
136 N97b66387e89e4824ab01bf087b28ae1b rdf:first sg:person.01370431444.02
137 rdf:rest Ncb94a20381f749679a102d5f1961100e
138 Na705ffc090c946c4a817dd67be479907 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Treatment Outcome
140 rdf:type schema:DefinedTerm
141 Naa1fa3907693411d85b57c96bf1f306c schema:name Radiation Dosimetry Systems RDS, Inc., Apharetta, GA, USA
142 rdf:type schema:Organization
143 Nc7d52f00f24541a4bb14de1dc8c3ac4f schema:name readcube_id
144 schema:value 94466b2b7e2a789e87aeb7814cbd53b2ba0049e56b84c0a64c553bf8b37b53ea
145 rdf:type schema:PropertyValue
146 Ncb94a20381f749679a102d5f1961100e rdf:first sg:person.013541325272.97
147 rdf:rest N46316fc5bcbd461fb2e2d3fd8abc514b
148 Nd3536140c6dc4ecabc2721152cd6eb10 rdf:first sg:person.01142772466.17
149 rdf:rest rdf:nil
150 Nd5172e3f8b1f4df08b59973e3f12e931 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Safety
152 rdf:type schema:DefinedTerm
153 Ndc5578bff0c14c5db6c6ec18f33f3e18 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Radiopharmaceuticals
155 rdf:type schema:DefinedTerm
156 Ne134e1993d4440de87f5eb8bfa41badf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Molecular Targeted Therapy
158 rdf:type schema:DefinedTerm
159 Ne2aa36bebdcf4d7d8e34ce9bc494e802 rdf:first sg:person.01107613315.44
160 rdf:rest Ne5202bda163e4bfe956e11c8aead4bcf
161 Ne353b3b8f7ec483e98b92fdd87579263 schema:name nlm_unique_id
162 schema:value 101140988
163 rdf:type schema:PropertyValue
164 Ne408980ac6f74fe985db9cc80f2d38f2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Aged
166 rdf:type schema:DefinedTerm
167 Ne5202bda163e4bfe956e11c8aead4bcf rdf:first sg:person.0634105510.51
168 rdf:rest N97b66387e89e4824ab01bf087b28ae1b
169 Ne68d9c6abbc04c4eb93d87e44ad556a5 schema:name doi
170 schema:value 10.1007/s00259-014-2713-y
171 rdf:type schema:PropertyValue
172 Nf9550ff1f6514b5e9d847c201cc38e9a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Prostatic Neoplasms
174 rdf:type schema:DefinedTerm
175 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
176 schema:name Medical and Health Sciences
177 rdf:type schema:DefinedTerm
178 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
179 schema:name Clinical Sciences
180 rdf:type schema:DefinedTerm
181 sg:journal.1297401 schema:issn 1619-7070
182 1619-7089
183 schema:name European Journal of Nuclear Medicine and Molecular Imaging
184 rdf:type schema:Periodical
185 sg:person.01107613315.44 schema:affiliation https://www.grid.ac/institutes/grid.5253.1
186 schema:familyName Hadaschik
187 schema:givenName Boris
188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01107613315.44
189 rdf:type schema:Person
190 sg:person.01142772466.17 schema:affiliation https://www.grid.ac/institutes/grid.7497.d
191 schema:familyName Haberkorn
192 schema:givenName Uwe
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142772466.17
194 rdf:type schema:Person
195 sg:person.01216712431.54 schema:affiliation https://www.grid.ac/institutes/grid.5253.1
196 schema:familyName Mier
197 schema:givenName Walter
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216712431.54
199 rdf:type schema:Person
200 sg:person.01252656365.95 schema:affiliation https://www.grid.ac/institutes/grid.5253.1
201 schema:familyName Zechmann
202 schema:givenName Christian M.
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01252656365.95
204 rdf:type schema:Person
205 sg:person.013541325272.97 schema:affiliation https://www.grid.ac/institutes/grid.5253.1
206 schema:familyName Debus
207 schema:givenName Jürgen
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013541325272.97
209 rdf:type schema:Person
210 sg:person.01370431444.02 schema:affiliation https://www.grid.ac/institutes/grid.7497.d
211 schema:familyName Kopka
212 schema:givenName Klaus
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01370431444.02
214 rdf:type schema:Person
215 sg:person.0601051525.56 schema:affiliation https://www.grid.ac/institutes/grid.5253.1
216 schema:familyName Afshar-Oromieh
217 schema:givenName Ali
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601051525.56
219 rdf:type schema:Person
220 sg:person.0634105510.51 schema:affiliation https://www.grid.ac/institutes/grid.280766.d
221 schema:familyName Joyal
222 schema:givenName John
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0634105510.51
224 rdf:type schema:Person
225 sg:person.0702220710.66 schema:affiliation https://www.grid.ac/institutes/grid.5386.8
226 schema:familyName Babich
227 schema:givenName John W.
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0702220710.66
229 rdf:type schema:Person
230 sg:person.0711165337.36 schema:affiliation https://www.grid.ac/institutes/grid.280766.d
231 schema:familyName Armor
232 schema:givenName Tom
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0711165337.36
234 rdf:type schema:Person
235 sg:person.0716664422.63 schema:affiliation Naa1fa3907693411d85b57c96bf1f306c
236 schema:familyName Stubbs
237 schema:givenName James B.
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716664422.63
239 rdf:type schema:Person
240 sg:pub.10.1038/bjc.2012.523 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003810699
241 https://doi.org/10.1038/bjc.2012.523
242 rdf:type schema:CreativeWork
243 https://app.dimensions.ai/details/publication/pub.1074708152 schema:CreativeWork
244 https://app.dimensions.ai/details/publication/pub.1077048096 schema:CreativeWork
245 https://app.dimensions.ai/details/publication/pub.1077061647 schema:CreativeWork
246 https://app.dimensions.ai/details/publication/pub.1083346985 schema:CreativeWork
247 https://doi.org/10.1002/ijc.2910620511 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045484440
248 rdf:type schema:CreativeWork
249 https://doi.org/10.1002/jcb.10661 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048747192
250 rdf:type schema:CreativeWork
251 https://doi.org/10.1016/0360-3016(91)90171-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1011986935
252 rdf:type schema:CreativeWork
253 https://doi.org/10.1016/s0022-5347(01)62921-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031823081
254 rdf:type schema:CreativeWork
255 https://doi.org/10.1021/bc200279b schema:sameAs https://app.dimensions.ai/details/publication/pub.1055154669
256 rdf:type schema:CreativeWork
257 https://doi.org/10.1021/jm800994j schema:sameAs https://app.dimensions.ai/details/publication/pub.1055955945
258 rdf:type schema:CreativeWork
259 https://doi.org/10.1111/j.1365-2559.2007.02635.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1004893542
260 rdf:type schema:CreativeWork
261 https://doi.org/10.1146/annurev-pharmtox-011112-140341 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046666670
262 rdf:type schema:CreativeWork
263 https://doi.org/10.1158/0008-5472.can-09-1682 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023217681
264 rdf:type schema:CreativeWork
265 https://doi.org/10.1158/1078-0432.ccr-1004-0023 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027571060
266 rdf:type schema:CreativeWork
267 https://doi.org/10.1158/1078-0432.ccr-12-3779 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032142025
268 rdf:type schema:CreativeWork
269 https://doi.org/10.1158/1078-0432.ccr-13-0231 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005760736
270 rdf:type schema:CreativeWork
271 https://doi.org/10.1200/jco.2004.09.154 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008865143
272 rdf:type schema:CreativeWork
273 https://doi.org/10.1200/jco.2005.05.160 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042646898
274 rdf:type schema:CreativeWork
275 https://doi.org/10.2967/jnumed.112.111203 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044994053
276 rdf:type schema:CreativeWork
277 https://doi.org/10.3322/caac.20107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009055747
278 rdf:type schema:CreativeWork
279 https://www.grid.ac/institutes/grid.280766.d schema:alternateName Progenics Pharmaceuticals (United States)
280 schema:name Molecular Insight Pharmaceuticals, Boston, MA, USA
281 rdf:type schema:Organization
282 https://www.grid.ac/institutes/grid.5253.1 schema:alternateName University Hospital Heidelberg
283 schema:name Department of Nuclear Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany
284 Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany
285 Department of Urology, University Hospital Heidelberg, Heidelberg, Germany
286 rdf:type schema:Organization
287 https://www.grid.ac/institutes/grid.5386.8 schema:alternateName Cornell University
288 schema:name Division of Radiopharmacy, Department of Radiology, Cornell University, New York, NY, USA
289 Molecular Insight Pharmaceuticals, Boston, MA, USA
290 rdf:type schema:Organization
291 https://www.grid.ac/institutes/grid.7497.d schema:alternateName German Cancer Research Center
292 schema:name Clinical Cooperation Unit Nuclear Medicine, DKFZ, Heidelberg, Germany
293 Department of Nuclear Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany
294 Division Radiopharmaceutical Chemistry, DKFZ, Heidelberg, Germany
295 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...